> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AbbVie Gets Priority Review on sNDA for Imbruvica
- URL: https://www.fdaweb.com/abbvie-gets-priority-review-on-snda-for-imbruvica/
- Published: 2018-06-25T12:00:00.000Z
- Updated: 2026-09-15T00:15:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141763

FDA accepts an AbbVie supplemental NDA for Imbruvica (ibrutinib) in combination with rituximab (Rituxan) as a new treatment option for Waldenström's macroglobulinemia, a rare and incurable blood cancer.